Benzinga | Oct 20, 2021 07:36AM EDT

KemPharm Announces Research Involving AZSTARYS And Serdexmethylphenidate To Be Featured In Poster Presentations At Multiple Medical Conferences During ADHD Awareness Month

KemPharm, Inc. (NASDAQ:KMPH), a specialty pharmaceutical company focused on the discovery and development of proprietary prodrugs, today announced that research involving AZSTARYS(r) and serdexmethylphenidate (SDX), the company's proprietary prodrug of d-methylphenidate (d-MPH), will be featured in poster presentations during multiple medical conferences being held in October (ADHD Awareness Month). Presentations will be given at the following conferences:



Event: American Academy of Child & Adolescent Psychiatry 68th Annual Meeting (AACAP 2021)Date: October 18-30, 2021 Single-Dose Pharmacokinetics of Serdexmethylphenidate/d-MethylphenidateTitle: Capsules in Children and Adolescents with ADHD and Healthy Adults: An Evaluation of Age and Body Weight



Event: Psych CongressDate: October 29-November 1, 2021 Steady-State Pharmacokinetics and Relative Bioavailability ofTitle: Serdexmethylphenidate/d-Methylphenidate, a Treatment for Attention-Deficit/Hyperactivity Disorder, Containing a Novel Prodrug of d-Methylphenidate